Eroglu Z, Kim Y, Gibney G, et al. Mature results of combination nivolumab (NIVO) plus ipilimumab (IPI) as adjuvant therapy in stage IIIC/IV melanoma (MEL). SMR 2017, abstract SMR09-06.
Camrelizumab plus rivoceranib versus sorafenib als eerstelijnsbehandeling bij inoperabel HCC
nov 2023 | Hepatologie, Immuuntherapie, Maag-darm-leveroncologie